Abstract a-Synuclein (a-syn) is an abundant presynaptic protein that is the primary constituent of inclusions that define Lewy body diseases (LBDs). In these inclusions, a-syn is phosphorylated at the serine-129 residue. Antibodies directed to this phosphorylation site are used to measure inclusion abundance and stage disease progression in preclinical models as well as in postmortem tissues in LBDs. While it is critical to reliably identify inclusions, phospho-specific antibodies often cross-react with nonspecific antigens. Four commercially available monoclonal antibodies, two from rabbits (clones EP1536Y and MJF-R13) and two from mice (81a and pSyn#64), have been the most widely used in detecting pS129-a-syn inclusions. Here, we systematically evaluated these antibodies in brain sections and protein lysates from rats and mice.
Tortosa, Irizarry, Gomez-Isla, & Hyman et al., 2000; Halliday, Hely, Reid, & Morris et al., 2008) . The accurate detection and estimation of a-syn inclusion abundance is fundamental to many pre-clinical and pathology studies. Herein, we performed systematic studies utilizing wild-type mice and rats harboring pS129-a-syn inclusions induced by the injection of short mouse a-syn fibrils together with a-syn knockout mice as controls. Short mouse a-syn fibrils are generated by aggregating monomeric a-syn into higher order pre formed fibrils which are then fragmented by sonication into short fibrils (Polinski et al., 2018) .
Once injected into the murine brains the short a-syn fibrils are internalized in neurons where they serve as a template for new fibers. Fibrilization results in hyper phosphorylation of serine 129-a-syn similar to LBs. Some evidence suggests that LBs may be hyper phosphorylated through the action of polo-like kinases (Waxman and Giasson, 2011) .
Therefore, pS129-a-syn provides a reliable epitope for the detection of pathological inclusions distinct from nonfibrillized a-syn present at high concentrations in many neurons.
Herein, we utilize a panel of tissue procured from mice and rats exposed to short a-syn fibrils, together with a-syn knockout mouse controls, to define the specificity and sensitivity of commercially available monoclonal antibodies. Through these studies, we provide recommendations for more reliable detection of pS129-a-syn inclusions in model systems.
| M E TH ODS

| Animals
All animal protocols and procedures were approved by the University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee. Sprague Dawley outbred rats were obtained from Taconic Farms, and C57BL/6 J mice and a-syn knockout mice were obtained from Jackson Laboratories.
| Antibody characterization
Ser(P)-129 a-syn antibodies and the antibody raised to total alpha synuclein were commercially available and purchased from Abcam (EP1536Y,81a, MJF-R13), Wako (pSyn#64), and BD Bioscience (Syn1).
Vendors report that the Ser(P)-129 a-syn monoclonal antibodies were raised against synthetic human a-synuclein peptide spanning 124-134 region with a phosphorylated Ser 129 residue. This peptide sequence was originally constructed by Fujiwara et al, and used in their seminal work that led to the discovery of extensive a-syn phosphorylation at Ser 129 reside in Lewy bodies (Fujiwara et al., 2002) . Monoclonal antibodies developed against synthetic a-syn aa 124-134 (phospho 129) peptide were validated using other antibodies that label Lewy bodies in post-mortem brain sections (Baba et al., 1998; Fujiwara et al., 2002) .
Clone EP1536Y is a monoclonal IgG antibody raised in rabbit and may be suitable for use in immunoblotting and immunohistochemistry (Arawaka, Sato, Sasaki, Koyama, & Kato, 2017; Perez-Revuelta et al., 2014; Prusiner et al., 2015; Tuttle et al., 2016) . Clone 81a is mouse IgG2a also used in immunoblot and immunohistochemistry applications (Dieriks et al., 2017; Tuttle et al., 2016) . MJF-R13 is a rabbit IgG monoclonal antibody used in immunoblotting experiments (Brahmachari et al., 2016) . Clone pSyn#64 is mouse IgG1 suitable for immunoblotting and immunohistochemistry (Jiang et al., 2016) . Clone Syn1 is mouse IgG1 raised to rat a-syn peptide aa 15-123, has not been further mapped within that peptide, but has been previously evaluated for specificity (Perrin et al., 2003) . For additional primary antibody information and secondary antibody information see Table 1 . Optimal secondary concentration was determined by serial dilution starting with the vendor recommendations. pS129-a-syn antibody concentration was confirmed using a BCA Protein Assay Kit (Pierce) with a g-globulin protein standard, and all antibodies diluted to working stock concentrations of 0.1 mg mL 21 .
| Injections and tissue processing
Eight-to ten-week mice and rats were anesthetized using isoflurane and bilaterally injected into the dorsal striatum with sonicated a-syn fibrils, a-syn monomer, or saline as described (Abdelmotilib et al., 2017) . Mice or rats were injected with 2 or 4 ml of solution, respectively, using a 32-gauge needle and Hamilton syringe over the course of 20 min. Solutions were injected in mice (and rats) in the right and left dorsal striatum at coordinates: 1.0 (0.7 rat) mm anterior and 1.85 (3.0 rat) mm lateral to the Bregma, and 3.0 (5.5 rat) mm ventral relative to the skull. Animals were anesthetized 6 months post injection with isoflurane and transcardially perfused with room temperature phosphate buffered saline solution (PBS, pH 7.4) and then 4% paraformaldehyde (PFA) in PBS. The 6-month time point was experimentally determined to have severe and wide-spread inclusion burden throughout much of the basal ganglia (Abdelmotilib et al., 2017) . Brains were removed and post-fixed in 4% PFA in PBS at 48C for 24 hr with agitation, and then soaked in a 30% sucrose/PBS for 24 hr at 48C. The brains were flash frozen in 2-methylbutane and later cut on a freezing sliding microtome into 40-micron sections.
| Immunohistochemistry
For immunohistochemistry with 3,3 0 -diaminobenzidine (DAB), sections were quenched with 0.6% H 2 O 2 in methanol for 45 min at room temperature (RT) with agitation. Following two 5 min washes with tris buffered saline (TBS, pH 7.4), sections were incubated in antigen retrieval buffer (10mM Na Citrate, 0.05% Tween-20, pH 6.0) at 378C for 1 hr at 40 rpm. Sections were washed with TBS 3 times for 5 mins and then blocked with 5% horse (or 5% goat serum), TBS, and 3% triton x-100 (or 0.3% triton x-100) for 1 hr. Sections were washed 2 3 5 min with TBS, and primary antibodies detecting a-syn phosphorylated on Ser129 were added in blocking solution containing 1% horse (or 1% goat serum), TBS, 0.1% triton x-100 (or 0.3% triton x-100) for 48 hr at 48C with agitation. After 2 rinses with TBS, secondary antibodies in blocking solution with 2.5% horse serum (or 2.5% goat serum), TBS, 0.1% triton x-100 (or 0.3% triton x-100) were added for 4 hr at 48C
with agitation. Sections were washed and then incubated for 1 min in For fluorescence, sections were washed twice with TBS and incubated in antigen retrieval buffer at 378C for 30 min on shaker 30 RPM and then blocked in 5% goat serum, TBS, and 0.3% triton x-100 for 1 hr. After two washes, primary antibodies at 20 ng mL 21 added in a blocking solution (5% goat serum, TBS, and 0.1% triton x-100) for 24 hr at 48C with agitation. Following three washes, the secondary antibodies (Alexa 488 conjugated goat anti rabbit or goat anti mouse) were added in a blocking solution (5% goat serum, TBS, and 0.1% triton x-100) for 24 hr at 48C with agitation. Sections were mounted on slides, and coverslips were applied using ProLong gold. Confocal images were captured using a Leica TCS-SP5
| Protein lysate preparation
Mice were perfused with 20 mL of ice cold PBS and the brains were removed. Brain tissue (150 mg) was placed in to 1 mL of TBS with 23 protease inhibitors and phosphatase inhibitors. Following 10 strokes of Dounce homogenization, samples were centrifuged for 10 min at 20,000 g at 48C. 500 ml of supernatant was then combined with 500 ml of 23 laemmli buffer to create PBS fraction lysate. The pellet was resuspended in 1 mL of TBS supplemented to 500 nM NaCl and 23 protease inhibitors and phosphatase inhibitors with 15 strokes of Dounce homogenization. The sample was then centrifuged for 10 min at 20,000 g at 48C, and 500 ml of supernatant was combined with 500 ml of 23 Laemmli buffer to create high salt fraction lysate. The pellet was resuspended in 1 mL of TBS supplemented to 500 nM NaCl, 1% triton x-100, 23 protease inhibitors and phosphatase inhibitors by vortexing for 30 s and rotating on a wheel for an hour. The sample was then centrifuged for 10 min at 20,000 g at 48C, and 500 ml of supernatant was combined with 500 mL of 23 Laemmli buffer to create Triton fraction lysate. The pellet was resuspended in 1 mL of TBS supplemented to 500 nM NaCl, 1% (w/v) SDS, 23 protease inhibitors and phosphatase inhibitors by sonicating for 20 s. The sample was then centrifuged for 10 min at 20,000 g at 48C, and 500 ml of supernatant was combined with 500 ml of 23 Laemmli buffer to create the SDS lysate fraction.
| Immunoblotting analysis
Samples were thawed on ice and boiled for 5 min at 908C. After use of crescendo, 20 ml of protein was loaded into a 10 well 4-20% gel. The gel was run at 100 mV for 1 hr, and transferred to a nitrocellulose membrane overnight at 48C. Following a rinse with TBS, nonspecific sites were blocked with 5% milk in TBST for 1 hr at RT. Primary antibodies were applied at 1:2,500 concentration in 5% milk in TBST overnight at 48C. Following three 5 min washes with TBST, secondary
antibodies were applied at a 1:10,000 concentration in 5% milk in TBST overnight at 48C. After three washes with TBST, the membrane was incubated with Crescendo for 1 min. Membranes were digitally imaged on a ChemiDoc system.
| RE S U L TS
3.1 | Reliability of a-syn inclusion detection in mouse and rat brain tissue using pS129-a-syn monoclonal antibodies
We and others have previously reported that injection with mouse derived pre-formed a-syn fibrils into the dorsal striatum of mice and rats causes profound a-syn inclusion pathology throughout the cortex and striatum (Abdelmotilib et al., 2017; Luk et al., 2012; MasudaSuzukake et al., 2014; Paumier et al., 2015; Shimozawa et al., 2017) . In contrast, a-syn knockout mice, or mice injected with only monomeric a-syn, do not develop these inclusions or pathology (Abdelmotilib et al., 2017; Luk et al., 2012; Masuda-Suzukake et al., 2014) . a-Syn inclusions can be distinguished from endogenous a-syn due to phosphorylation (compared to a-syn not in inclusions) at the a-syn S129
residue. To compare four commercially available pS129-a-syn antibodies (Table 1 ) in brain sections from mice and rats, we used the antibodies at three concentrations (1, 10, and 100 ng mL
21
) with methods previously used for the antibody clone 81a in mouse tissue (Abdelmotilib et al., 2017) . All antibodies robustly labeled inclusions in both the cortex and striatum at the 10 ng mL 21 concentration (Figure 1 ). Severe signal loss occurred for all antibodies at 1 ng mL 21 and no differences in signal for inclusions was observed between 10 and 100 ng mL 21 in either mouse or rat brains ( Figure 5 ). In serial sections from the same mice, clones 81a and EP1536Y produced similar inclusion staining patterns. Prominent serpentine inclusions of significantly length were labeled with equal intensities as somal skein-like, often perinuclear, inclusions that could occupy much of the cytoplasm. In contrast, MJF-R13 and pSyn#64 showed more punctate perinuclear staining, with much weaker profiles of serpentine inclusions in the same affected tissue, particularly in neuron processes.
In cortical and striatal sections from a-syn knockout mice, or in wild-type mice injected with monomeric protein, clone EP1536Y did not produce appreciable signal (Figure 1a) . However, clone 81a, in both
Assessment of pSer129-a-Syn and inclusion detection in mouse brain. Wild-type and a-syn knockout mice (C57bl/6J) were injected bilaterally into the striatum with 10 mg of a-syn pre-formed fibrils or monomeric protein as previously described (Abdelmotilib et al., 2017) . Brain sections were evaluated from mice six months later. Representative widefield images of DAB-staining (converted to grayscale for contrast) with the indicated monoclonal antibody (left margins) in animals injected with (a) fibrils in wild-type mice, (b) fibrils in a-Syn knockout mice, or (c) monomer protein in wild-type mice. All antibodies were included at 10 ng mL Occasional cell processes reminiscent of endothelia were also labeled by 81a (Figure 1-7 7 ) . However, this pattern of staining was not prominent in sections from fibril-injected mice and abundant pS129-a-syn inclusions. These results suggest that in the absence of a specific epitope, at 10 ng mL
, the 81a antibody binds more nonspecifically presumably to lower-affinity epitopes. In the striatum, clone 81a labeled axon bundles known as Wilson's pencils, both in control and in fibril injected sections (Figure 1 10 ,b 12 ). Clone MJF-R13 also produced nonspecific staining different than 81a in the cortex and striatum in a-syn knockout sections or wild-type mice injected with monomeric a-syn. 3.2 | a-syn monoclonal antibodies intensely label intracellular bodies in the a-syn knockout brain
In a-syn models as well as in human post-mortem tissue, a-syn inclusions are not always abundant and can be rare, yet the presence of rare inclusions can be profoundly important for interpretation. Because of the amount of staining we observed in the a-syn knockout mouse that cannot be accounted for by species-antibody (secondary) detection problems (Figure 2 ), we wondered whether there were sparse offtarget staining features that could potentially be confused with pS129-a-syn inclusions. Serial sections across the whole a-syn knockout mouse brain were evaluated. Outside of the weaker off-target neuronal process staining associated with antibody clone 81a, more intense but rare small deposits of signal could be observed sparsely but uniformly through the somatosensory cortex (Figure 4a ). In contrast, in brains that lacked pS129-a-syn inclusions, these structures could not be detected (Figure 1 ). The off-target signals in the knockouts highlighted different intracellular deposits with morphology different from the nearby motor cortex, although with similar intensity, and were typically smaller than pS129-a-syn inclusions. In both the somatosensory and motor cortex, clone MJF-R13 developed punctate intracellular staining profiles throughout the neuronal perikarya in many neurons ( Figure   4b ). MJF-R13 also labeled sparse intracellular puncta in both the insular cortex and nucleus accumbens. While pSyn#64 demonstrated exceptional overall specificity, occasional staining was observed under highmagnification analysis in very small (e.g., less than 5 microns) intracellular deposits in the motor, somatosensory, and insular cortices. Thus, we find that in the absence of the pS129-a-syn antigen, clones MJF-R13, FIG URE 3 Assessment of pSer129-a-Syn and inclusion detection in rat brain. Wild-type Sprague Dawley rats (SDTac) were injected bilaterally into the striatum with 20 mg of a-syn pre-formed fibrils or monomeric protein as previously described (Abdelmotilib et al., 2017) . Brain sections were evaluated from rats 6 months later. Representative widefield images of DAB-staining (converted to grayscale for contrast) with the indicated monoclonal antibody (left margins) in animals injected with (a) fibrils in wild-type rats, (b) saline control in wild-type rats, and (c) monomer protein in wild-type rats. All antibodies were included at 10 ng mL 21 concentration. Coronal sections are shown within 1 mm of Bregma, with primary motor cortex (ctx) and dorsal striatum (str) shown at two different magnifications. Scale bars are 0.1 mm
| 1983 pSyn#64 and 81a nonspecifically labeled different intracellular features in cells, some common and some rare, all with different morphologies.
In contrast, antibody clone EP1536Y did not develop any significant labeled features in the a-syn knockout brain, even at higher concentrations in wild-type mouse brain that lacked inclusions. Therefore, EP1536Y shows the highest specificity for immunohistochemistry of pS129-a-syn inclusions, as well as comparable sensitivity to clone 81a.
| Off-target pS129-a-syn staining titrates with the staining of a-syn inclusions
We next determined whether it was possible to further titrate the pS129-a-syn antibody so that inclusions and not the off-targets we described could be labeled However, in lowering the concentration of antibody to 1 ng mL
21
, pS129-a-syn a-syn inclusions were poorly labeled and difficult to image, even with the two antibodies that most intensely labeled inclusions (clones 81a and EP1536Y, Figure 1 -5).
Increasing the concentration to 100 ng mL 21 did not improve the labeling of inclusions but greatly increased off-target and nonspecific staining profiles ( Figure 5 ). Similar results with clones MJF-R13 and pSyn#64 were obtained, with off-target staining increasing at the 100 ng mL 21 concentration. These results show it is not possible, using the staining conditions and blocking agents described here, to titrate offtarget and nonspecific signals from the labeling of pS129-a-syn inclusions.
FIG URE 4
Assessment of pSer129-a-syn monoclonal antibodies in a-syn knockout mice. Coronal brain sections were obtained from adult (3-6 months) a-syn knockout mice and evaluated with the monoclonal antibody indicated in the left margin (a, b, c), all used at 10 ng mL 21 .
Representative images from DAB staining (grayscale shown for contrast) are shown. Insets black bounding boxes show higher magnifications of features of interest. Scale bars are 0.1 mm
| pS129-a-syn monoclonal antibodies highlight different inclusion morphologies
Immunohistochemistry results with typical widefield microscopy show that the monoclonal antibodies differentially labeled the inclusions. To further investigate these differences in inclusion density and morphometry, we next obtained confocal images with optimal pinhole settings for a 633 objective with a numerical aperture of 1.4. Evaluation of single Z-planes through the inclusions revealed that clones 81a and EP1536Y labeling in a continuous swirl pattern that extended to the top and bottom borders of the neuron. As in widefield analysis, when stacked together these perinuclear structures presented as lesscomplex spheroids with decreased core density (Figure 6a,b) . In contrast, pSyn#64 always labeled intense puncta along the skeins, with few or no instances of convincing serpentine structures in processes.
These results suggest pSyn#64 does not continuously label across the fibrils and therefore explains the different morphologies observed in widefield microscopy. A widely used and highlyspecific monoclonal antibody directed to total a-syn, Syn1, demonstrated that most a-syn protein (18 kDa) could be detected in the triton X-100 extracted fraction in our protocol ( Figure 7 ). As expected, in using anti-mouse secondary antibody with mouse brain lysate from nonperfused animals, weak heavy and light-chain signals for immunoglobulin were also detected in using mouse monoclonals 81a and pSyn#64. Antibody EP1536Y robustly detected a band near the expected size of nonphosphorylated a-syn in the most soluble fraction, just under the 20 kDa marker (19 kDa), and this band was absent in the a-syn knockout lysates. Most of the endogenous pS129-a-syn was present in the saline-extracted fraction and did not need detergent for solubilization like total a-syn protein. pS129-a-syn could also be detected by EP1536Y in the triton-solubilized fraction, although it cannot be excluded that EP1536Y partially cross-reacts with nonphospho a-syn. These results show that endogenous pS129-a-syn is highly soluble and therefore subject to loss in standard tissue staining approaches that involve permeabilization of tissue and detergents.
Off-target binding of proteins other than a-syn was noted for all antibodies except for the Syn1 monoclonal to a-syn. Clone 81a detected a very robust band 78 kDa present exclusively in the SDSextracted brain fraction whereas MJF-R13 detected an unknown protein of 120 kDa exclusively in the saline-solubilized fraction. On   FIG URE 6 Confocal analysis of pS129 a-syn-positive inclusions in mice and rats. C57Bl/6J wild-type mice and Sprague Dawley wild-type rats were injected bilaterally into the striatum with either 10 mg or 20 mg (respectively) of a-syn fibrils and frozen brain sections analyzed 6 months later. Confocal images were obtained from a single plane with a 633 objective set for optimal pinhole. Red color indicates pS129-a-syn staining (Cy3) and blue color indicates DAPI. The monoclonal antibody used at 20 ng mL 21 are given in the left margin. Images from both the primary motor cortex (cortex) and dorsal striatum (striatum) were obtained. Scale bar is 50 lm longer exposures, MJF-R13 developed a high-molecular weight smear of protein labeling (e.g., >150 kDa extending to the top of the gel) that was comparable in both the a-syn knockout as well as wild-type mouse brain lysate. Clone EP1536Y also detected an off-target protein equally present in the soluble and triton-extracted fraction, similar to a-syn, of 105 kDa in size. pSyn#64 cross-reacted only weakly with highermolecular weight bands (160 kDa), but the signal from the secondary-alone antibody was stronger than these off-target interactions. In summary, these results show that all of the pS129-a-syn monoclonal antibodies cross-react with proteins unrelated to a-syn and/or fail to detect pS129-a-syn protein in immunoblots from wildtype mouse brain lysates.
| D ISC USSION
In this study, we compared commercially available monoclonal antibodies directed to the pS129-a-syn residue in the reliability and sensitivity of a-syn inclusion detection in rats and mice. Notably, different methods of preparing the tissue such as different antigen retrieval methods and blocking agents may affect antibody performance. Under the common conditions applied to all antibodies, inclusions were uniformly robustly detected at concentrations of 10 ng mL 21 and higher in both mice and rat brains while significant loss of signal was detected at 1 ng mL
21
. Clones 81a and EP1536Y detected similar inclusion profiles and densities in serial sections, whereas inclusions revealed by pSyn#64 and MJF-R13 were more limited and punctate in appearance. Problematic off-target staining, revealed in the a-syn knockout but also in wildtype mice and rats, titrated together with the labeling of inclusions in rodents exposed previously to a-syn fibrils. Some of these off-target proteins may have been detected by immunoblot, with all antibodies cross-reacting with different proteins that differ in size and solubility from that of a-syn.
Clone EP1536Y was the only antibody able to detect endogenous pS129-a-syn via immunoblot, and pS129-a-syn was much more soluble than total a-syn. As very little total a-syn was detected in the saline-only soluble fraction, these results are consistent with pS129-a-syn constituting a small fraction of total a-syn. As all antibodies were raised against close variations of the same peptide, it is reasonable to conclude that EP1536Y has a higher affinity than the other antibodies toward the peptide conformation of the pS129-a-syn epitope as present on membranes in immunoblots. Some studies have reported improved success of a-syn peptide detection on immunoblots by changing the peptide conformations via fixation with paraformaldehyde or other cross-linking fixatives (Lee and Kamitani, 2011) . It is possible that with additional protocol refinement, for example, higher pH antigen retrieval buffer compared to pH 6.0 retrieval buffer used herein, the other monoclonal antibodies may be adapted to detect pS129-a-syn with better sensitivity than that reported here.
Here, we focused on rodent models because we could utilize knockout mice as definitive controls as well as rats treated with fibrils to induce robust pS129-a-syn positive inclusions in a controlled way.
Rats also provide an additional source of brain tissue different than the species used to generate the antibody to avoid the potential problem of cross-reactive immunoglobulins. Rutherford et al. recently presented a strong case that off-target interactions inherent to the antibody clone 81a has led to an overestimation of inclusion burden in several studies (Rutherford, Brooks, & Giasson, 2016) . In high-magnification imaging, we can confirm that clone 81a cross-reactivity is high, but is also unambiguously distinct from pS129-a-syn inclusions formed in neurons from exposure to fibrils. The other antibody clones did not share the offtarget profiles of clone 81a. The biggest difference in pS129-a-syn inclusions from off-target intracellular staining is the small size of features associated with off-target staining in the cytosol, as well as the lack of filaments in neuronal processes and lack of clear skein structures in the perikarya.
In many studies, the small molecule thioflavin is used to confirm the presence of b-sheets that typify authentic amyloid. However, thioflavin has relatively weak affinity to most protein fibrils in cells that are typically in the mid-micromolar range (Lindberg, Wranne, Gilbert Gatty, Westerlund, & Esbjorner, 2015; Sulatskaya, Kuznetsova, & Turoverov, 2011; Ye et al., 2008) compared to all the monoclonal antibodies used here that show affinities in the low nanomolar to femptomolar range.
Curiously, thioflavin-T and related molecules show high-affinity binding to a-syn fibrils in vitro but much lower to negligible affinity to inclusions in neurons (Ye et al., 2008 showed the same staining pattern as a-syn knockout animals, it could be argued that a-syn knockout animals may not be required for approaches where signal from control animals can be subtracted. However, the success of using wild-type and/or a-syn knockout animals as a background control depends on the labeled off-target proteins being stable in expression in disease states, and this is probably not the case for at least one suspected off target, phosphorylated neurofilament light-chain (Rutherford et al., 2016) . Thus, high-magnification approaches that consider morphometries of inclusions may be the best way to quantify inclusion abundance. Further complicating interpretation is that brain sections filled with many inclusions may render antibodies less-available to off-target interactions, thereby compressing a signal (inclusions) to noise (off-targets) ratio.
Although all antibodies were raised to the same phosphorylated site in a-syn, the antibodies unexpectedly differed in their ability to fully label inclusions. EP1536Y and 81a produced fuller and more connected skeins through the neuronal cytoplasm as well as in processes, compared to pSyn#64 and MJF-R13. Due to the probable interaction of 81a with neurofilaments that titrate together with pS129-a-syn in inclusions (Rutherford et al., 2016) , we therefore can conclude that EP1536Y is the antibody with the highest specificity and sensitivity of those tested. Warranting caution, EP1536Y detects an off-target higher-molecular weight protein unrelated to a-syn, but this protein was apparently not detected via immunohistochemistry or confocal approaches. Other tissue-chemistry protocols that might potentially unmask the cross-reactive EP1536Y epitope as seen in immunoblots could potentially confound interpretation with this antibody.
Outside of a-syn inclusions, we confirm the existence of endogenous pS129-a-syn only through immunoblots with EP1536Y. Unexpectedly, most of the endogenous pS129-a-syn protein appeared in a highly soluble protein fraction, released with only gentle Dounce homogenization in saline. Since this is the fraction of protein most difficult to retain in tissue-staining protocols, washed away with even small amounts of detergents, the innate biology of pS129-a-syn may also explain why it is incredibly difficult to localize within brain tissue.
Unequivocally, phosphatases that normally remove phosphate from S129 lose their ability to interact when a-syn refolds into fibrils in cells.
It is tempting to speculate that the more soluble and nonmembrane bound a-syn subunits, like pS129-a-syn, are those more likely to participate in the formation of inclusions (Lue et al., 2012; Walker et al., 2013) . Unfortunately, most observations regarding the biology of pS129-a-syn have been made using phospho-mimetic and phosphonull mutations in the S129 residue that may not preserve the temporal aspects of pS129-a-syn as well as the unique solubility profile. With the comparative analysis of the available monoclonal antibodies presented here, we hope that these observations and recommendations enable more definitive conclusions from both past and future studies that unravel the biology of a-syn in disease.
| C ONC LUSI ON S
Antibody EP1536Y demonstrates the best reliability and pS129-a-syn inclusion detection sensitivities in mouse and rat brain, although usage of several antibodies in parallel is recommended to ensure reliability of results. Given the off-target and nonspecific patterns of staining with all the antibodies, we did not obtain evidence that endogenous pS129-a-syn outside of inclusions could be labeled in brain sections.
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